Measuring the effects of intravenous scopolamine on the human EEG in healthy volunteers

The University of Auckland0 个研究点目标入组 12 人开始时间: 2022年2月9日最近更新: 2022年4月25日

试验速览

暂无简介。

•Male or female, aged 18 years or above and less than 60.
•In the Investigators’ opinion, is able and willing to comply with all trial requirements.
•Participant is willing and able to give informed consent for participation in the trial.

•Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.
•Regular use of any medication deemed to be contraindicating as judged by the attending study clinicians.
•Contraindication to the use of scopolamine or glycopyrrolate according to manufacturer guideline
•Significant renal or hepatic impairment.
•Participants with glaucoma
•Cardiovascular conditions including abnormal heart rate and blood pressure checked at screening.
•History of psychiatric illness.
•Any unstable medical or neurologic condition.
•Problematic substance dependence in previous 3 months
•Inability to speak or read English.
•Any other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the trial.

发起方